A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

More recently, they’ve discovered some of these same genes can raise a man’s risk for prostate cancer, too. If you carry a gene that could be involved in the development of prostate cancer ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...

Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Johnson & Johnson (JNJ) posts Phase 3 trial win for Akkega plus prednisone in metastatic castration-sensitive prostate cancer ...

Standard medical practice is to not test men who have a life expectancy of less than 10 years for prostate cancer.